Sage Historical Financial Ratios
| SAGE Stock | USD 5.55 0.02 0.36% |
Sage Therapeutic is promptly reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 11.59, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.81 will help investors to properly organize and evaluate Sage Therapeutic financial condition quickly.
Sage |
About Sage Financial Ratios Analysis
Sage TherapeuticFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Sage Therapeutic investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Sage financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Sage Therapeutic history.
Sage Therapeutic Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Sage Therapeutic stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Sage Therapeutic sales, a figure that is much harder to manipulate than other Sage Therapeutic multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Earnings Yield
The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.Most ratios from Sage Therapeutic's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.At present, Sage Therapeutic's PB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Payables Turnover is expected to grow to 0.22, whereas Book Value Per Share is forecasted to decline to 11.59.
| 2022 | 2023 | 2024 (projected) | Graham Number | 63.5 | 52.16 | 36.38 | Receivables Turnover | 0.56 | 1.02 | 1.08 |
Sage Therapeutic fundamentals Correlations
Click cells to compare fundamentals
Sage Therapeutic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sage Therapeutic fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 534.32 | 4.04 | 395.66 | 294.29 | 15.0 | 14.25 | |
| Ptb Ratio | 3.88 | 2.17 | 1.44 | 1.81 | 1.62 | 1.7 | |
| Book Value Per Share | 18.58 | 39.87 | 29.47 | 21.12 | 13.36 | 11.59 | |
| Free Cash Flow Yield | (0.0597) | (0.15) | 0.15 | (0.2) | (0.42) | (0.4) | |
| Operating Cash Flow Per Share | (10.4) | 12.78 | (6.45) | (7.76) | (9.03) | (8.58) | |
| Stock Based Compensation To Revenue | 22.31 | 0.0862 | 16.59 | 8.01 | 0.85 | 0.81 | |
| Pb Ratio | 3.88 | 2.17 | 1.44 | 1.81 | 1.62 | 1.7 | |
| Ev To Sales | 521.27 | 2.57 | 351.94 | 274.7 | 14.24 | 13.52 | |
| Free Cash Flow Per Share | (10.51) | 12.77 | (6.45) | (7.77) | (9.04) | (8.59) | |
| Roic | (0.69) | 0.28 | (0.26) | (0.41) | (0.72) | (0.68) | |
| Net Income Per Share | (12.79) | 11.66 | (7.68) | (8.49) | (9.05) | (9.5) | |
| Payables Turnover | 0.0262 | 0.15 | 0.0529 | 0.0429 | 0.21 | 0.22 | |
| Sales General And Administrative To Revenue | 50.35 | 0.18 | 29.09 | 29.63 | 3.18 | 3.02 | |
| Research And Ddevelopement To Revenue | 53.7 | 0.26 | 44.89 | 42.44 | 4.12 | 3.91 | |
| Capex To Revenue | 0.84 | 3.1E-4 | 0.059 | 0.12 | 0.006396 | 0.006077 | |
| Cash Per Share | 19.84 | 40.39 | 29.7 | 21.46 | 12.59 | 12.18 | |
| Pocfratio | (6.94) | 6.77 | (6.6) | (4.92) | (2.4) | (2.52) | |
| Capex To Operating Cash Flow | (0.0109) | 5.19E-4 | (9.84E-4) | (0.002037) | (0.001023) | (0.001074) | |
| Pfcf Ratio | (6.87) | 6.77 | (6.59) | (4.91) | (2.4) | (2.52) | |
| Days Payables Outstanding | 13.9K | 2.4K | 6.9K | 8.5K | 1.7K | 1.7K | |
| Income Quality | 0.78 | 1.1 | 0.83 | 0.86 | 1.0 | 0.68 | |
| Roe | (0.69) | 0.29 | (0.26) | (0.4) | (0.68) | (0.64) | |
| Ev To Operating Cash Flow | (6.77) | 4.31 | (5.87) | (4.59) | (2.28) | (2.39) | |
| Pe Ratio | (5.64) | 7.42 | (5.54) | (4.49) | (2.39) | (2.51) | |
| Return On Tangible Assets | (0.6) | 0.28 | (0.25) | (0.37) | (0.61) | (0.64) | |
| Ev To Free Cash Flow | (6.7) | 4.31 | (5.86) | (4.58) | (2.27) | (2.39) | |
| Earnings Yield | (0.0844) | (0.18) | 0.13 | (0.22) | (0.42) | (0.4) | |
| Net Debt To E B I T D A | 0.13 | (2.61) | 0.6 | 0.28 | 0.12 | 0.11 | |
| Current Ratio | 9.23 | 31.58 | 21.14 | 12.82 | 10.51 | 10.16 | |
| Tangible Book Value Per Share | 18.58 | 39.87 | 29.47 | 21.12 | 13.36 | 11.59 | |
| Graham Number | 73.13 | 102.26 | 71.38 | 63.5 | 52.16 | 36.38 | |
| Shareholders Equity Per Share | 18.58 | 39.87 | 29.47 | 21.12 | 13.36 | 11.59 | |
| Capex Per Share | 0.11 | 0.006637 | 0.006341 | 0.0158 | 0.009242 | 0.00878 | |
| Graham Net Net | 17.09 | 38.72 | 28.13 | 19.33 | 12.28 | 11.04 | |
| Revenue Per Share | 0.14 | 21.43 | 0.11 | 0.13 | 1.44 | 1.37 | |
| Enterprise Value Over E B I T D A | (5.07) | 4.57 | (4.86) | (3.87) | (2.26) | (2.37) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.